Foghorn Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Collaboration revenue	$8,153	$7,808	$21,662	$19,746
Operating expenses:
Research and development	20,002	24,689	63,420	74,020
General and administrative	6,652	6,971	20,753	22,006
Impairment of long-lived assets	—	—	—	2,398
Total operating expenses	26,654	31,660	84,173	98,424
Loss from operations	(18,501)	(23,852)	(62,511)	(78,678)
Other income, net:
Interest income	2,032	3,495	7,033	8,804
Other income, net	620	1,235	2,859	2,757
Total other income, net	2,652	4,730	9,892	11,561
Net loss	$(15,849)	$(19,122)	$(52,619)	$(67,117)
Net loss per share attributable to common stockholders—basic and diluted	$(0.25)	$(0.31)	$(0.84)	$(1.28)
Weighted average common shares outstanding—basic and diluted	63,029,293	62,602,848	62,952,723	52,241,942
Comprehensive loss:
Net loss	$(15,849)	$(19,122)	$(52,619)	$(67,117)
Other comprehensive gain (loss):
Unrealized gains (losses) on marketable securities	68	698	(111)	1,186
Total other comprehensive gain (loss)	68	698	(111)	1,186
Total comprehensive loss	$(15,781)	$(18,424)	$(52,730)	$(65,931)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.